Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus

Lupus

Volumn 16, Issue 2, 2007, Pages 95-100

  Andre, J M ^a   Cimaz, R ^b,c   Ranchin, B ^b   Galambrun, C ^a   Bertrand, Y ^a   Bouvier, R ^b   Rieux Laucat, F ^d   Trescol Biemont, M C ^e   Cochat, P ^b,c   Bonnefoy Berard, N ^e  

^a HÔPITAL DEBROUSSE   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

Author keywords

Apoptosis; B cells; Bcl 2; Bfl 1; Lupus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FAS ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; THALIDOMIDE;

ANAMNESIS; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BFL 1 GENE; CASE REPORT; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; DNA MICROARRAY; DRUG DOSE INCREASE; DRUG MEGADOSE; ERYTHEMA; FAMILIAL DISEASE; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PEDIGREE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33847363103     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306075382     Document Type: Article

References (15)

1. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004; 3: 505-509.
2. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 18-24.
3. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24: 321-352.
4. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003; 10: 124-133.
5. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107-1113.
6. Del-Rey M, Ruiz-Contreras J, Bosque A et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood 2006; 108: 1306-1312.
7. Mehrian R, Quismorio FP Jr, Strassmann G et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998; 41: 596-602.
8. Johansson C, Castillejo-Lopez C, Johanneson B et al. Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families. Genes Immun 2000; 1: 380-385.
9. Trescol-Biemont MC, Verschelde C, Cottalorda A, Bonnefoy-Berard N. Regulation of A1/Bfl-1 expression in peripheral splenic B cells. Biochimie 2004; 86: 287-294.
10. Cottalorda A, Verschelde C, Marcais A et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 2006; 36: 1684-1693.
11. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11: 1693-1698.
12. Feuerhake F, Kutok JL, Monti S et al. NF{kappa}B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392-1399.
13. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
14. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005: 113: 730-737.
15. Baker KP. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun Rev 2004; 3: 368-375.